Skip to content
TrialScanner

NCT05231785

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Phase 1RecruitingALNYLead

Registry record

Lead sponsor
Alnylam Pharmaceuticals
Conditions
Early-Onset Alzheimer Disease
Primary completion
Jan 11, 2029Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05231785 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05231785: A Study to Evaluate the... | TrialScanner